Pharmacodynamic parameter estimates of midazolam according to the sigmoid Emax model (equation 5)
| Arterial traditional | Venous traditional | Venous extended | |
|---|---|---|---|
| E0(μV/sec) | 78 ± 4 | 90 ± 5 | 91 ± 5 |
| EC50 (ng/ml) | 104 ± 11 | 86 ± 11 | 89 ± 11 |
| Emax (μV/sec) | 151 ± 4 | 167 ± 6 | 166 ± 5 |
| γ | 0.83 ± 0.06 | 0.78 ± 0.07 | 0.81 ± 0.07 |
| k eo (min−1) | 0.32 ± 0.062 | 313 ± 110 | 2.5 ± 2.0 |
| k vo (min−1) | 1.4 ± 0.9 | ||
| ς2 | 720 ± 45 | 1060 ± 50 | 1050 ± 50 |
| −2LL | 3175 | 3913 | 3908 |
Arterial or venous concentrations were used to drive the pharmacokinetic-pharmacodynamic fit using the traditional or extended effect compartment model. No significant differences were observed in pharmacodynamic estimates P < .05 by analysis of variance).